omidenepag   Click here for help

GtoPdb Ligand ID: 10315

Synonyms: DE-117 (omidenepag isopropyl ophthalmic solution) | Omlonti® | UR-7276 | UR7276
Approved drug
omidenepag is an approved drug (FDA (2022))
Compound class: Synthetic organic
Comment: Omidenepag acts as a selective agonist of the prostanoid EP2 receptor [5]. It is administered as an opthalmic solution containing omidenepag isopropyl (which is named DE-117) in clinical studies [4,6]. Omidenepag isopropyl has PubChem CID 44230999.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 138.17
Molecular weight 478.14
XLogP -0.15
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)CNc1cccc(n1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)n1cccn1
Isomeric SMILES OC(=O)CNc1cccc(n1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)n1cccn1
InChI InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31)
InChI Key YHGSTSNEOJUIRN-UHFFFAOYSA-N
References
1. Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N. (2021)
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Jpn J Ophthalmol, 65 (6): 810-819. [PMID:34495425]
2. Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. (2020)
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Am J Ophthalmol, 220: 53-63. [PMID:32533949]
3. Aihara M, Ropo A, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams N. (2020)
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Jpn J Ophthalmol, 64 (4): 398-406. [PMID:32572719]
4. Kaplan TM, Sit AJ. (2022)
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials.
Expert Opin Emerg Drugs, 27 (3): 321-331. [PMID:35924872]
5. Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, Shimazaki A, Matsugi T, Shams N, Zhang JZ. (2018)
Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
Invest Ophthalmol Vis Sci, 59 (1): 145-153. [PMID:29332128]
6. Matsuo M, Matsuoka Y, Tanito M. (2022)
Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Clin Ophthalmol, 16: 1261-1279. [PMID:35510270]